News stories about Protagonist Therapeutics (NASDAQ:PTGX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Protagonist Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 43.2115870413161 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

PTGX has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. BMO Capital Markets dropped their price objective on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, October 19th. BidaskClub lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus initiated coverage on shares of Protagonist Therapeutics in a research note on Monday, January 29th. They issued a “buy” rating and a $32.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Protagonist Therapeutics presently has an average rating of “Hold” and an average target price of $32.50.

Protagonist Therapeutics (PTGX) opened at $17.58 on Monday. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $23.75.

In other news, CFO Thomas P. O’neil sold 8,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $20.00, for a total transaction of $160,000.00. Following the transaction, the chief financial officer now directly owns 4,000 shares in the company, valued at $80,000. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Richard S. Shames sold 3,529 shares of the business’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $20.50, for a total transaction of $72,344.50. Following the transaction, the insider now owns 3,529 shares in the company, valued at $72,344.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,944 shares of company stock worth $319,839. Company insiders own 15.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/12/protagonist-therapeutics-ptgx-earns-coverage-optimism-rating-of-0-06.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.